Pune, Maharastra -- (SBWIRE) -- 09/09/2015 -- Summary

DelveInsight Report, “Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2015” emphasizes on the currently active CAR-T cell products in research and development. The Report covers the 35+ companies which are active in this field including 14 leading companies with 35 products targeting 20 different antigens and 9 different technologies. The Report provides in-depth analysis on the CAR-T cell profiles covering pre-clinical and clinical studies, Collaborations details and Deal values, Technologies and Targeted antigens. The Report provides the CAR-T licensing opportunities, acquisitions, market drivers and barriers followed by SWOT Analysis. Report also describes the unmet needs covered by CAR-T cells highlighting the adverse events, which are major concerns in the market for the usage of CAR-T cells.

Report Highlights:

- CAR-T cell Therapy Pipeline scenario

- Collaborations & partnering deals

- Current Prominent Research Areas and Key Players

- Pipeline product profiles CAR-T Technologies and Targeted Antigens

- Licensing opportunities

- Market Drivers and Barriers

Complete report available @ http://www.rnrmarketresearch.com/chimeric-antigen-receptor-car-t-cell-immunotherapy-competitive-landscape-technology-and-pipeline-analysis-2015-market-report.html.

Scope

- Overview of the global CAR-T cell therapy pipeline scenario, products and associated companies information

- Coverage of global CAR-T cell therapies under development

- Competitive landscape of products for key players and related indications

- Coverage of licensors, collaborators and Development partners, deal terms and deal values estimation

- Pipeline analysis across different phases, emerging trends and comparative analysis of pipeline products with detailed clinical profiles, mechanism of action, route of administration and molecule type, along with product development activities

- Highlights of licensing & collaboration opportunities and funding details

- Highlights of latest CAR-T technologies and innovative companies

- Key topics covered include strategic competitor assessment, barriers and drivers in the market along with SWOT analysis

Reason to buy

- Pipeline intelligence and complete understanding over therapeutics development of CAR-T cell products to exploit opportunities

- Explore outcomes of Pre-clinical and clinical studies and Identify prominent therapeutic areas

- Develop & design strategies to gain competitive advantage by tracking the latest CAR-T technologies and associated innovative companies

- Track in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Uncovering opportunities in the rapidly growing market, Optimize portfolio, keep updated and make the best decisions for business development

- Identifying the upcoming leaders and products in the CAR-T cell therapy market in the coming years

- Understand the CAR-T competitive landscape, plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Inquire for discount on this report @ http://www.rnrmarketresearch.com/contacts/discount?rname=393810.

Table of Contents

1 Report Introduction 3

2 Executive Summary Snapshot 9

3 Executive Summary 10

4 Introduction 12

4.1. Chimeric antigen receptor (CAR) T-cells 12

4.2. History 12

4.3. CARs and Generations 12

4.4. Advantages of CAR-T cells 17

4.5. Adverse Events with CAR T-cell Therapy 17

5 Car-T Cell Therapy-Analysis 18

5.1. CAR-T Collaboration Deals 18

5.1.1. CAR-T Cells Therapy Collaborations and Deal Year 18

5.1.2. Collaborations & Deal Value Trends 20

5.1.3. Companies collaborations for future developments 22

5.2. CAR-T Acquisitions Deals 24

5.2.1. CAR-T Cells Therapy Acquisitions Trends 24

5.2.2. CAR-T Cells Therapy Acquisitions Offerings by Big Giants 25

5.3. New facility for the development of CAR-T cells 26

5.4. CAR-T Licensing Opportunities 27

5.5. Pipeline Scenario 28

5.5.1. Pipeline Products under Development-An Overview 28

5.5.2. Pipeline Products under Development by Company 29

5.5.3. CAR T-cells Therapeutic Areas & Companies 31

5.5.4. CAR-T cells Targeted Antigens 34

5.5.5. CAR-T Therapies-Clinical trials & Completion Year 37

5.5.6. CAR T-cell Technologies & Companies Involved 39

5.5.7. CAR-T Safety Switches & Company involved 41